Literature DB >> 15664543

The neuro-ophthalmology of multiple sclerosis.

Elliot M Frohman1, Teresa C Frohman, David S Zee, Roderick McColl, Steven Galetta.   

Abstract

Multiple sclerosis (MS) is the most common disabling neurological disease in young people. Most CNS lesions involve neuroanatomically non-eloquent zones that often do not result in symptomatic complaints. By contrast, tissue-injury mechanisms involving inflammatory demyelination can involve more eloquent sites, such as the optic nerve and brainstem, which can correspondingly produce the development of well recognised syndromes such as optic neuritis and internuclear ophthalmoplegia, respectively. In this review we discuss the broad landscape of abnormalities that affect the afferent visual system and the ocular motor apparatus, and emphasise relevant features, the recognition and treatment of which are of importance to general neurological practice. The commonness of visual sensory and eye movement abnormalities in MS highlights the importance of understanding the principles addressed in this review.

Entities:  

Mesh:

Year:  2005        PMID: 15664543     DOI: 10.1016/S1474-4422(05)00992-0

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  66 in total

Review 1.  Optical coherence tomography (OCT): imaging the visual pathway as a model for neurodegeneration.

Authors:  Kristin M Galetta; Peter A Calabresi; Elliot M Frohman; Laura J Balcer
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

2.  Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis.

Authors:  Stephanie B Syc; Shiv Saidha; Scott D Newsome; John N Ratchford; Michael Levy; E'tona Ford; Ciprian M Crainiceanu; Mary K Durbin; Jonathan D Oakley; Scott A Meyer; Elliot M Frohman; Peter A Calabresi
Journal:  Brain       Date:  2011-10-17       Impact factor: 13.501

Review 3.  Optical coherence tomography: a window into the mechanisms of multiple sclerosis.

Authors:  Elliot M Frohman; James G Fujimoto; Teresa C Frohman; Peter A Calabresi; Gary Cutter; Laura J Balcer
Journal:  Nat Clin Pract Neurol       Date:  2008-12

4.  Management of optic neuritis in Canada: survey of ophthalmologists and neurologists.

Authors:  Edward J Atkins; Carolyn D Drews-Botsch; Nancy J Newman; Olivier Calvetti; Seegar Swanson; Valérie Biousse
Journal:  Can J Neurol Sci       Date:  2008-05       Impact factor: 2.104

5.  [Multiple sclerosis. An update with practical guidelines for ophthalmologists].

Authors:  T Ziemssen; H Wilhelm; F Ziemssen
Journal:  Ophthalmologe       Date:  2006-07       Impact factor: 1.059

6.  From Imaging the Brain to Imaging the Retina: Optical Coherence Tomography (OCT) in Schizophrenia.

Authors:  Carlos Schönfeldt-Lecuona; Thomas Kregel; Arno Schmidt; Elmar H Pinkhardt; Florian Lauda; Jan Kassubek; Bernhard J Connemann; Roland W Freudenmann; Maximilian Gahr
Journal:  Schizophr Bull       Date:  2015-06-05       Impact factor: 9.306

7.  Summary of eye examinations of 284 patients with multiple sclerosis.

Authors:  Jan M Roodhooft
Journal:  Int J MS Care       Date:  2012

8.  Transgenic inhibition of astroglial NF-kappa B improves functional outcome in experimental autoimmune encephalomyelitis by suppressing chronic central nervous system inflammation.

Authors:  Roberta Brambilla; Trikaldarshi Persaud; Xianchen Hu; Shaffiat Karmally; Valery I Shestopalov; Galina Dvoriantchikova; Dmitry Ivanov; Lubov Nathanson; Scott R Barnum; John R Bethea
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

9.  Optic Neuritis: A Model for the Immuno-pathogenesis of Central Nervous System Inflammatory Demyelinating Diseases.

Authors:  Gregory F Wu; Chelsea R Parker Harp; Kenneth S Shindler
Journal:  Curr Immunol Rev       Date:  2015

10.  Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy.

Authors:  Lindsay Horton; Amy Conger; Darrel Conger; Gina Remington; Teresa Frohman; Elliot Frohman; Benjamin Greenberg
Journal:  Neurology       Date:  2013-04-24       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.